Additionally, ITP patients experienced a similar prevalence of stroke regardless of if they were specifically denoted to have been treated with TPO-RAs or not, supporting the continued use of TPO-RAs in management. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.